Targeted Deletion of the MLC1f/3f Downstream Enhancer Results in Precocious MLC Expression and Mesoderm Ablation  by Jiang, Ping et al.
Developmental Biology 243, 281–293 (2002)
doi:10.1006/dbio.2002.0574, available online at http://www.idealibrary.com onTargeted Deletion of the MLC1f/3f Downstream
Enhancer Results in Precocious MLC
Expression and Mesoderm Ablation
Ping Jiang,1 Jihwan Song,2 Guoqing Gu,3 Esfir Slonimsky, En Li,
and Nadia Rosenthal4
Cardiovascular Research Center, Massachusetts General Hospital and Harvard
Medical School, 149 13th Street, Charlestown, Massachusetts 02129
The expression of skeletal muscle contractile proteins is tightly regulated during embryonic development. In the mouse, the
myosin light chain (MLC) 1f/3f gene locus is not activated until E9.5, exclusively in skeletal muscle precursor cells. A
potent enhancer downstream of the MLC1f/3f locus confers correct temporal and spatial activation of linked reporter gene
in transgenic mouse embryos. To examine roles of the MLC downstream enhancer (MLCE) in its native context of the
MLC1f/3f gene locus, we eliminated a 1.5-kb DNA segment containing the enhancer from the mouse genome by targeted
deletion, leaving no exogenous sequences at the deletion site. Mouse embryos homozygous for the MLCE deletion were
smaller and developmentally delayed, formed no mesoderm by E7.5, and were resorbed almost completely at E8.5. In situ
hybridization and RT-PCR analyses of affected mutant embryos at E7.5 revealed ectopic MLC transcripts, whose products
would be predicted to interfere with a variety of nonmuscle cell functions determining differentiation of mesoderm. These
results suggest that the MLC downstream enhancer and its flanking sequences include negative regulatory elements which
block precocious activation of MLC expression in mesodermal precursors during a critical window of development, as well
as positive elements which subsequently permit tissue-restricted MLC transcription in differentiating skeletal
muscles. © 2002 Elsevier Science (USA)
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Morphogenesis during development involves a highly
orchestrated series of changes in the shape and position of
individual cells before they differentiate. Cellular func-
tions, such as cytokinesis, cortical contraction during mi-
gration, capping of receptors, and vesicle transportation, are
critical to this early developmental process, and depend on
the molecular composition and structure of the cytoskel-
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All rights reserved.eton. Cytoskeletal isoforms of contractile proteins, such as
actin and myosin, are the motor molecules of undifferenti-
ated cells, and the regulated expression and interactions of
those proteins determine the proper function of the cy-
toskeleton.
The subsequent activation of contractile protein expres-
sion in committed muscle cells is tightly regulated during
development. The alkali light chains MLC1f and MLC3f are
encoded by a single gene which uses discrete promoters and
alternative splicing to produce two mRNAs (Periasamy et
al., 1984; Robert et al., 1984; as illustrated in Fig. 1a).
Activation of MLC1f transcription at E9.5 (Lyons et al.,
1990; Grieshammer et al., 1992) is controlled by a down-
stream enhancer (MLCE) located 24 kb away from MLC1f
promoter, which confers correct temporal and spatial acti-
vation of reporter genes during development (Donoghue et
al., 1988; Rosenthal et al., 1989). A detailed analysis of the
MLCE revealed that the enhancer contains multiple recog-
nition motifs for binding of transcription factors involved in
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myogenesis (Rosenthal et al., 1990). These sites are well
conserved among vertebrates, indicating the importance of
the enhancer function in developmental and tissue-specific
regulation of MLC1f promoter.
The role of the MLCE on activation and levels of tran-
scription from the MLC3f promoter, which is 15 kb distal to
the enhancer, is still unclear. In transgenic mice, the 260-bp
mouse MLCE core activates the MLC3f promoter (2-kb
region) in the somitic myotome, 4 days earlier than endog-
enous MLC3f expression, which is activated at E14 in
skeletal muscle (Kelly et al., 1995). The action of the MLCE
on MLC3f promoter activity during cardiac muscle devel-
opment in transgenic mice is complex. Mcgrew et al. (1996)
demonstrated that the rat MLC downstream enhancer abol-
ishes rat MLC3f promoter activity in developing cardiac
muscle, whereas in another study, activation of the mouse
MLC3f promoter was observed in the developing heart at as
early as E7.5 in a transgene containing the mouse MLCE
(Kelly et al., 1995). The conflicting results may be due
either to the species differences (rat vs. mouse) or to the
different size of MLC3f promoter regions used (0.6 vs. 2 kb),
or both. A second enhancer was recently reported in intron
1 of the MLC1f/3f gene locus with activity only in fetal
(E13.5–birth) skeletal muscle development and in adult
muscle, not in embryonic myogenesis (E9–E13.5) (Kelly et
al., 1997). Therefore, it is still unclear how the differential
activation of MLC1f/3f is regulated by the MLC down-
stream enhancer during development.
In an effort to elucidate the molecular mechanisms
underlying transcriptional regulation of the MLC1f/3f locus
during development, we generated the MLCE-null mice by
targeted deletion. Using a similar strategy, functions of
cis-acting control elements in other gene loci have been
examined, such as the 5HS2 element in the -globin locus
control region (Leighton et al., 1995) and an enhancer
downstream of the H19 and Igf2 genes (Fiering et al., 1995).
Our targeting strategy was different from that described in
these two reports since no selection marker and/or exog-
enous DNA sequences were retained in the place of the
deleted MLCE. The unexpected early embryonic lethality
resulting from the homozygous MLCE deletion, accompa-
nied by the ectopic activation of the MLC1f/3f locus, has
generated new testable models of the MLCE function dur-
ing development, and suggests that normal cytoskeletal
structure, cell proliferation, and cell motility in early de-
velopment may be disrupted by the precocious presence of
muscle-specific contractile protein isoforms.
MATERIALS AND METHODS
Construction of Targeting Vectors
The mouse 129/Sv genomic library in Lambda Fix II phage vector
(Stratagene) was screened with a probe of 920-bp DNA sequences
containing the rat MLCE (Donoghue et al., 1988). A 14-kb genomic
fragment was obtained and subcloned into the NotI site of pBlue-
script KS (Stratagene). Sequencing confirmed that the fragment
contains the mouse MLCE core sequences conserved between rat
and mouse. Two targeting vectors were generated in order to delete
the enhancer completely while introducing no selection marker
and exogenous sequences in the place of the enhancer. In targeting
vector 1, a 4.0-kb PGK-neo-tk cassette (gift from Dr. Hong Wu) was
inserted into EcoRI site, 3 of the enhancer, and the resultant
targeting vector contained a 17.6-kb fragment (Fig. 1b). Targeting
vector 2 was constructed by deleting a 1.5-kb AccI–EcoRI fragment
containing the MLC enhancer and flanking sequences (mainly 5
region) directly from the cloned genomic fragment, resulting in a
12.1-kb fragment in the vector (Fig. 1b).
Culture, Transfection, and Positive and Negative
Selection of ES Cells
J1 ES cells were cultured in DMEM (with high glucose and
pyruvate, Gibco) with 20 mM Hepes, 14 mM sodium bicarbonate,
0.1 mM nonessential amino acids (Gibco), 0.1 mM -mercap-
toethanol, 15% fetal calf serum (HyClone), 500 U/ml ESGRO
(Gibco), and penicillin–streptomycin. ES cells were maintained on
a feeder layer of mitotically inactivated mouse embryonic fibro-
blasts as described (Li et al., 1992).
For transfection of ES cells with targeting vector 1, 5  107 J1 ES
cells were dispersed by trypsin digestion, washed, and resuspended
in electroporation buffer containing 20 mM Hepes, 137 mM NaCl,
5 mM KCl, 0.7 mM Na2HPO4, 6 mM glucose, and 0.1 mM
-mercaptoethanol. BamHI-linearized targeting vector 1 (25 g)
was mixed with ES cells, and the DNA/cell suspension was
incubated on ice for 10 min and electroporated at 400 V and 25 F
in a Gene Pulser (Bio-Rad). After electroporation, ES cells were
incubated on ice for 10 min and plated on ten 100-mm dishes
seeded with a feeder layer. After 24 h, the culture medium was
supplied with G418 to a concentration of 400 g/ml. Selection was
continued for 10 days. Through the positive selection, the homolo-
gous recombination resulted in one allele “marked” with PGK-
neo-tk cassette immediately downstream of the MLCE in the ES
cells.
To delete the MLCE by targeting, ES cells derived from positive-
selected colony P4C3 (Fig. 1c) were suspended with 25 g BamHI-
linearized targeting vector 2 and electroporated under identical
conditions as for targeting vector 1. After 24 h of electroporation, 4
M ganciclovir (Syntex) was added to the culture medium. Resis-
tant colonies were picked after 8 days of negative selection. The
allele “marked” with PGK-neo-tk cassette was thereby replaced
with the deletion allele lacking the MLCE carried on targeting
vector 2.
Blastocyst Injection and Generation of Chimeras
and MLCE/ Heterozygotes
Blastocyst injection and generation of chimeras were previously
described (Li et al., 1992). Briefly, 15–20 ES cells of a single clone
carrying the MLCE targeted deletion were injected into C57BL/6J
blastocysts at E3.5, cultured at 37°C for 1 h, and were then
transferred into uteri of pseudopregnant B6CBAF1/J female at 2.5
days postcoitum. The resultant chimeric male animals were back-
crossed to C57BL/6J. Heterozygous animals were identified by
Southern blot analysis of tail genomic DNA. F1 heterozygous male
and female were crossed to generate homozygotes. F2 heterozygotes
derived from different F1 parents were also intercrossed to obtain F3
offspring. For timed pregnancies, the day on which a vaginal plug
was detected was considered to be E0.5.
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Southern Blot Analysis of Genomic DNAs
To identify homologous recombination, genomic DNAs were
prepared from each clone of ES cells and analyzed by Southern blot.
Briefly, ES cells were lysed in 100 mM NaCl (pH 7.5), 10 mM
Tris–HCl, 5 mM EDTA, 0.5% SDS, and 0.20 mg/ml proteinase K
(Gibco) at 55°C for overnight. Lysates were extracted once with
phenol/chloroform (Sigma), and genomic DNAs were precipitated
with ethanol. DNA was digested with XbaI, and 10 g digests were
electrophoresed, blotted, and hybridized with a 3 probe of a 400-bp
fragment (Fig. 1c) outside the targeting vectors. The probe was
labeled with DIG-dUTP via random primed labeling (Boehringer
Mannheim). Mice and embryos were genotyped by Southern blot
analysis with the same probe as above. Genomic DNAs from tail
biopsies and embryos were similarly prepared as described (Li et al.,
1992). For genotyping mutant embryos and their normal litter-
mates at E7.5, genomic DNAs were prepared from a pool of 17
mutant embryos of several litters and from a pool of normally
developed littermates of a single litter. A total of 6.5 g genomic
DNA was obtained from pooled mutant embryos.
Histological Analysis
Uteri containing embryos of F1 intercross were isolated at E6.5,
E7.5, and E8.5 in phosphate-buffered saline (PBS), fixed in 4%
paraformaldehyde overnight at 4°C, dehydrated through a graded
ethanol series, and cleared in xylene, and decidua were individually
embedded in paraffin. The staging of embryos was based on the
timing of embryo isolation (E0  midnight). Serial sections (7 m)
were collected on Superfrost/Plus slides (Fisher Scientific), stained
with hematoxylin/eosin, examined, and photographed under a
Zeiss Axiophot microscope.
Whole-Mount in Situ Hybridization
Embryos were dissected in PBS and fixed in MEMFA (0.1 M
Mops, pH 7.5, 2 mM EGTA, 1 mM MgSO4, 3.7% formaldehyde) for
2 h at room temperature. The procedure for whole-mount in situ
hybridization was essentially the same as previously described
(Wilkinson, 1992), except that Blocking Reagent (Boehringer Mann-
heim) and maleic acid buffer were used during antibody incubation
and washing steps. Digoxigenin-labeled antisense RNA probes
were generated following the manufacturer’s instruction (Boeh-
ringer Mannheim). The plasmid containing the probe of Brachyury
was linearized with BamHI and transcribed by using T7 RNA
polymerase (Wilkinson et al., 1990). The probe specific for both
MLC1f and MLC3f was a 293-bp PCR product corresponding to
exons 2 and 3 (specific for MLC3), and exons 5 and 6 (common to
both MLC1f and MLC3f), from mouse skeletal muscle cDNA as
described (McGrew et al., 1996). Antisense MLC1f/3f RNA probe
was in vitro transcribed with T3 RNA polymerase from the
BamHI-linearized construct. Embryos were examined and photo-
graphed under a dissecting stereomicroscope (WILD MZ8; Leica).
RT-PCR Analysis
Isolation of total RNA was carried out with the RNAqueous-
4PCR kit (Ambion). Total RNAs were isolated from a pool of 7 E7.5
mutant embryos, and from pools of 16, 8, and 2 E7.5, E8.5 and E9.5
wild-type embryos, respectively. RT-PCR was performed with the
ProSTAR RT-PCR kit (Stratagene). Due to the low levels of
transcripts obtainable from these small embryos, we first per-
formed PCR to amplify 420-bp products of -actin with 5-
ATGGGTCAGAAGGACTCCTATGT-3 and 5-GACTTGGCTG-
GCCGGGACCTGA-3primers, using RT templates from wild-
type and mutant embryos. The yield of the -actin PCR products
was visualized on gels after 40 cycles of amplification. We then
normalized template input for the subsequent MLC-specific PCR
to the amounts of -actin RT-templates obtained from wild-type
and mutant embryos. The MLC1f/3f product (308-bp product) was
amplified by using 5 (GATCACCTTAAGTCAGGT) and 3
(GCAACGCTTCTACCTCTT) primers corresponding to MLC se-
quences of exon5 and exon7, respectively, for 35 cycles. Equal
aliquots of -actin and MLC1f/3f wt or mutant PCR products were
combined and loaded into a single lane of a 2.4% agarose gel.
RESULTS
Targeted Deletion of the MLC Downstream
Enhancer in ES Cells
To delete the MLCE from its native locus, a 14-kb
fragment containing exons 5–9 (out of a total of 9 exons in
the MLC1f/3f locus) and the MLC downstream enhancer
(Fig. 1a) was cloned from a murine 129/Sv genomic library
and subjected to restriction mapping (Fig. 1b). The strategy
for the targeted deletion of this enhancer was premised on
the possibility that interruption of noncoding regulatory
regions, containing multiple DNA binding motifs (Rosen-
thal et al., 1990), with a selection marker or exogenous
DNA sequences could provide novel targets for unknown
cis- or trans-acting factors, potentially confounding the
interpretation of phenotypes in the mutant animals. Our
concern was heightened by a report in which retention of a
neo-resistant selection marker in the place of 5HS2 of the
-globin locus control region resulted in an embryonic
lethal phenotype, which was abrogated upon removal of the
selection marker (Fiering et al., 1995).
To avoid such a potential problem, we removed the MLC
downstream enhancer by homologous recombination in
two consecutive steps (Fig. 1b). In the first step, a PGK-
neo-tk cassette (Wu et al., 1994) was inserted immediately
3 to the enhancer and the resulting targeting vector 1 was
used for replacement of one of the wild-type MLCE alleles
in J1 ES cells through G418 selection (positive selection). Of
the 110 G418 resistant clones isolated, 13 carried the allele
“marked” with the PGK-neo-tk gene, as demonstrated by
the presence of a 13-kb XbaI fragment in addition to the
wild-type allele of a 9-kb XbaI fragment using a 3 probe
(Fig. 1c). In the second step, targeting vector 2, a 12.1-kb
fragment with deletion of the MLCE and its flanking
sequences (1.5-kb AccI–EcoRI fragment), was electropo-
rated into one (P4C3) of the ES cell clones with the
“marked” allele from the first step. After ganciclovir selec-
tion (negative selection), only one (the clone #30) of 800
surviving clones screened had the “marked” allele replaced
by the deletion allele, seen as a 7.5-kb XbaI fragment using
the same 3 probe (Fig. 1c). A 5 probe was also used to
analyze the genomic DNA from the clone #30 ES cells,
revealing that the labeled DNA restriction fragment was
283Targeted Deletion of MLC1f/3f Downstream Enhancer
© 2002 Elsevier Science (USA). All rights reserved.
284 Jiang et al.
© 2002 Elsevier Science (USA). All rights reserved.
FIG. 2. Comparison of the MLCE/ mutant embryos with their normal littermates by hematoxylin/eosin histology. Embryos derived
from F1 heterozygote intercrosses were isolated at E6.5, E7.5, and E8.5 (E0  midnight). Normal embryos are shown in (a) (E6.5), (d) (E7.5),
and (g) (E8.5). The MLCE/ mutant embryos are shown in (b) and (c) (E6.5), (e) and (f) (E7.5), and (h) and (i) (E8.5). (j) (normal embryo, E7.5)
and (k) and (l) (mutant embryos, E7.5) show the morphology of cells in extraembryonic endoderm at a high magnification, and two-sided
vacuoles are seen in cells of extraembryonic endoderm in the mutant embryos compared with one-sided vacuoles in a normally developed
littermate. ac, amniotic cavity; am, amnion; ch, chorion; ec, ectoplacental cone; ee, embryonic ectoderm; em, embryonic mesoderm; eee,
extraembryonic endoderm. Scale bar, 100 m (a–i).
FIG. 1. Targeted deletion of the MLCE in ES cells. (a) Organization of the mouse MLC1f/3f genomic locus and generation of MLC1f and
MLC3f transcripts by alternative splicing. The cloned 14-kb Sau3AI-fragment containing exons 5–9 and the MLCE is shown. (b) Restriction
map of genomic region containing MLC1f/3f exons 5–9 and the MLCE, and schematic targeting strategy to delete the MLCE in ES cells with
no selection marker and exogenous DNA sequences retained. Step 1: A PGK-neo-tk cassette was inserted immediately 3 of the enhancer
and the resultant targeting vector 1 was used for replacement of one of the wild-type allele in J1 ES cells through G418 selection (positive
selection). Step 2: Targeting vector 2 contains a 12.1-kb genomic fragment which lacks a 1.5-kb AccI–EcoRI fragment containing the MLCE
and flanking sequences (mainly 5 region). This deletion construct was introduced into ES cells which have a allele “marked” with a
PGK-neo-tk cassette from Step 1, and these ES cells were selected in medium containing ganciclovir (negative selection). (c) Southern
analysis of XbaI-digested genomic DNA and expected size of restriction fragments in heterozygous ES cells. After Step 1, a 400-bp 3 probe
detected a 9-kb wild-type band and a 13-kb band representing the “marked” allele. In Step 2, the ES cell clone P4C3 from Step 1 was used,
and a 7.5-kb band representing the allele with the deleted MLCE was detected by the same 3 probe in addition to the 9-kb wild-type band
in ES cells of the clone #30. A, AccI; B, BamHI; E, EcoRI; Sa, Sau3AI; S, SmaI; X, XbaI; MLCE, the MLC downstream enhancer. Restriction
sites in brackets were destroyed during steps of subcloning.
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indistinguishable from that of wild-type ES cells (data not
shown). This strategy resulted in a “clean” deletion of the
1.5-kb AccI–EcoRI MLC downstream enhancer fragment
from the otherwise unmodified MLC1f/3f locus.
Heterozygous Mice Lacking One Copy of the MLC
Downstream Enhancer Are Normal
To generate mice carrying the MLCE deletion, ES cells
from the clone #30 were injected into C57BL/6J blastocysts,
which were then transferred into the uteri of pseudopreg-
nant B6CBAF1/J female foster mice. Of the five male
chimeras obtained, two were germ-line chimeras. The in-
tercross of male chimeras/female C57BL/6J resulted in 88
offspring, 51% of which were heterozygous (MLCE/), and
the remaining 49% were wild type (MLCE/) as deter-
mined by Southern blot analysis. Heterozygous animals
were fertile and appeared normal, with no obvious pheno-
type.
Homozygous Deletion of the MLC Downstream
Enhancer Results in Early Embryonic Lethality
To generate mice homozygous for the MLCE deletion, F1
heterozygous mice were intercrossed and F2 progeny were
genotyped at weaning by Southern blot analysis. Of 180
animals from 26 litters, 127 (70.6%) were heterozygous, 50
(27.7%) were wild type, and only 3 (1.7%) were homozygous
(MLCE/; Table 1), suggesting that the majority of ho-
mozygous animals died in utero. To determine the devel-
opmental stage at which lethality occurred, embryos of five
litters from F1 heterozygous intercrosses were examined at
different times of gestation, from E9.5 to E11.5 (Table 1). Of
the 43 decidua examined, 31 (72%) contained morphologi-
cally normal embryos, of which 19 (44%) were heterozy-
gous and 12 (28%) were wild type. The remaining 12
decidua were much smaller and contained no embryonic
structures, indicating that the putative homozygous con-
cepti were resorbed by E9.5. The putative homozygous
mutants from E8.5 pregnancies were nearly all resorbed as
well (data not shown), suggesting that mutant embryos died
before this stage. The dissection of embryos at E7.5 revealed
morphological mutants which were much smaller than
their normal littermates (see Figs. 3a and 3b). The number
of the morphological mutants corresponded to 24% of total
embryos isolated from 13 litters (Table 1). Based on the
overall statistical analysis of offspring derived from the
intercross of F1 heterozygotes, the morphological mutants
represented homozygous animals, as proven by genotyping
(Fig. 3g). We also obtained a total of 63 animals derived from
intercrosses of F2 MLCE/ heterozygotes. These F3 animals
were genotyped at weaning by Southern analysis, which
revealed 35 heterozygotes (55.6%), 27 wild type (42.8%),
and 1 homozygote (1.6%). The low percentage of surviving
homozygotes was not changed in F3 generations when
comparing with that in F2 generations.
Developmental Deficiency in the MLC Downstream
Enhancer-Null Embryos during
Early Embryogenesis
To elucidate the morphological defects resulting from
homozygous deletion of the MLCE, histological examina-
tion was carried on the embryos during early gestation.
Embryonic tissue from F1 heterozygous intercross was
histologically sectioned and stained with hematoxylin/
eosin at E6.5, E7.5, and E8.5. As shown in Figs. 2a–2c,
MLCE/ mutant embryos at E6.5–E7.0 were obviously
smaller than their normal littermates. By this stage, wild-
type embryos were entering gastrulation with the egg
cylinder filling the yolk sac cavities. The primitive streak
had appeared at the stage of wild-type embryos with well-
formed endoderm and ectoderm. In contrast, the mutant
embryos were at least five times smaller, with a large
portion of yolk sac cavity unoccupied. No primitive streak
appeared, but both ectoderm and endoderm were formed.
However, the morphology of cells in the endoderm was
abnormal, showing double-sided vacuoles. By E7.5 (Figs.
2d–2f and 2j–2l), the differences between wild-type and
mutant embryos were much more striking and the relative
size of mutant embryos was even smaller (at least 10 times
smaller than their normal littermates). Wild-type embryos
developed well-defined mesoderm, whereas the mutant em-
bryos were developmentally arrested and contained
TABLE 1
The Offspring from Intercrosses of F1 Heterozygous Animals (MLCE/) and Genotypes
Age Litter No. of animal Resorbed Mutant
Genotype
/ / /
3 wk 26 180 50 (27.7%) 127 (70.6%) 3 (1.7%)
E9.5–E11.5 5 43 12 (28%) 0 12 (28%) 19 (44%) 0
E8.5 1 8 2 0 N/D N/D N/D
E7.5 13 116 0 28 (24%) N/D N/D N/D
Note. Genotyping was done by Southern Blot using tail DNA for adults and embryonic DNA for embryos. For the litters of E9.5–E11.5,
one litter was from E9.5 and two were from E10.5 and E11.5, respectively. N/D, not determined.
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no mesoderm. The abnormal double-sided vacuoles in
endodermal cells first seen at E6.5 were clearly visible in
the mutant embryos at E7.5. By E8.5, the mutant embryos
were in the process of resorption (Figs. 2g–2i).
To further document the absence of mesoderm in
MLCE/ mutant embryos, expression of Brachyury, one of
the earliest mesodermal markers (Herrmann, 1991), was
examined in embryos from E7.5 by whole-mount in situ
hybridization. As shown in Figs. 3c and 3d, the Brachyury
gene was expressed in the region of primitive streak (poste-
rior mesoderm) of normal embryos. However, no expression
of Brachyury was detected in mutant embryos. The absence
of a mesodermal layer in MLCE/ mutant embryos was
thus confirmed at the molecular level.
Precocious Expression of MLC1f/3f Transcripts in
the MLC Downstream Enhancer-Null Embryos
The early embryonic lethality of MLCE/ mutant em-
bryos was unexpected, since transcription from the mouse
MLC1f/3f locus is normally not detected until E9.5, and
then only rostrally in the myotome of the most mature
somites. Moreover, the MLC downstream enhancer has
been shown to confer appropriate developmental regulation
of MLC1 promoter-driven reporter gene activation in nu-
merous transgenic animals (Rosenthal et al., 1989; Grie-
shammer et al., 1992). We first examined MLC1f/3f tran-
scripts in adult musculature by ribonuclease protection
assay, using a 293-bp antisense probe as described (McGrew
et al., 1996) (see Materials and Methods). This analysis (data
not shown) demonstrated that the expression levels of both
MLC1f and MLC3f in skeletal muscles were indistinguish-
able among wild-type, heterozygous, and surviving ho-
mozygous animals, indicating that deleting the enhancer
had no obvious effect on MLC1f/3f transcription in surviv-
ing MLCE/ adults.
In the course of this analysis, we also detected MLC1f/3f
transcripts in the developing heart of E8.5 wild-type em-
bryos (Fig. 4). These transcripts presumably arise from the
MLC3f promoter, which has been previously shown to be
active in the developing heart (Kelly et al., 1995 and
McGrew et al., 1996). This observation documents cardiac-
specific transcription of MLC3f at an earlier embryonic
stage than previously reported (E10.5; Kelly et al., 1995, and
E11.5; McGrew et al., 1996).
To explore the possibility that homozygous mutant phe-
notype arose from precocious expression of the enhancer-
less MLC1f/3f loci, we analyzed MLC1f/3f expression in
E7.5 embryos derived from F1 MLCE/ heterozygote inter-
crosses, and in a control litter of wild-type embryos, at E7.5,
E8.5, and E9.5 by whole-mount in situ hybridization using
the same antisense probe. As seen in previous studies,
MLC1f/3f transcripts were not detected in developing
somites of wild-type embryos until E9.5 (Fig. 4). In contrast,
MLC transcription was activated at E7.5 in MLCE/ mu-
tant embryos, while no MLC expression was detectable in
their MLCE/ or MLCE/ normal littermates (Figs. 3e and
3f). In addition, the precocious activation of MLC1f/3f loci
in mutant embryos were also demonstrated with the more
sensitive RT-PCR analysis (Fig. 4). Notably, the deleted
enhancer contains tissue-restricted inhibitory elements
(Ceccarelli et al., 1999), which may suppress precocious
activation of the MLC1f/3f locus in the presomitic meso-
derm until myogenic differentiation has occurred.
DISCUSSION
To elucidate the roles of various cis-regulatory elements
in the establishment of temporally and spatially restricted
MLC1f/3f gene expression patterns during skeletal muscle
development, we eliminated the MLC downstream en-
hancer from the mouse genome by targeted deletion. Un-
expectedly, the null mutation in both alleles resulted in
early embryonic lethality. Detailed analyses revealed that
the development of homozygous mutant embryos was
severely retarded and only a very small percentage devel-
oped beyond E7.5. The MLCE/ mutant embryos at E7.5
were much smaller than their normal littermates and
lacked a primitive streak and mesoderm.
The MLCE-null phenotype might result from failure to
activate another gene, proximal to the MLC1f/3f locus, also
under the control of the MLC downstream enhancer. The
gestational timing of the mutant phenotype argues against
this explanation, however. Although MLC3f transcripts are
present in the embryonic heart by E8.5, neither MLC1f nor
MLC3f transcription is activated at earlier stages in normal
embryos. Moreover, a 920-bp MLCE fragment did not
activate linked transgenic reporters before E9.5 in the
myotome (Rosenthal et al., 1989; Grieshammer et al.,
1992), consistent with the normal timing of MLC1f gene
activation in skeletal muscle. The precocious expression of
MLC gene products in E7.5 MLCE/ mutant embryos,
normally expressed only in postmitotic muscle tissue,
might interfere with normal premyogenic cell function in
the developing mesoderm. This model predicts that the
1.5-kb region excluded in these mice contains cis-acting
negative regulatory elements which serve to suppress the
MLC1f/3f locus during early stages of mesodermal develop-
ment.
Mechanisms of Precocious MLC Activation
The colocation of negative regulatory elements with
positively acting enhancers is not unprecedented. Suppres-
sor sites flank an immunoglobulin heavy-chain enhancer
(Scheuermann and Chen, 1989), and a cis-regulatory ele-
ment with the dual function of either silencing or enhanc-
ing transcription has been described in the nervous system
(Bessis et al., 1997). Although the precise identity of puta-
tive suppressor elements in the sequences flanking the
MLC downstream enhancer has yet to be characterized,
mutation of an evolutionarily conserved E box within the
enhancer core resulted in elevated levels of linked reporter
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FIG. 3. In situ hybridization analyses of MLCE/ mutant embryos. (a, b) Developmental arrest and retardation in the MLCE/ mutant
embryos. MLCE/ mutant embryo and normally developed littermates were dissected from F1 heterozygous intercross at E7.5. The mutant
embryo is significantly smaller than the normal littermates. (c, d) Expression of Brachyury in embryos at E7.5 using digoxigenin-labeled
antisense RNA probes. Brachyury transcripts were not detected in the mutant embryo, compared with the normally developed littermates.
(e, f) Expression of MLC transcripts in embryos at E7.5. A 293-bp digoxigenin-labeled antisense probe corresponding to a cDNA fragment
including exons 2 and 3 (specific for MLCf3) and exons 5 and 6 (common to both MLC1f and MLC3f) detected MLC1f/3f transcripts in the
mutant embryos but not in the normally developed littermates. (g) Southern blot analysis of XbaI-digested genomic DNA of embryos at
E7.5. Since normally developed embryos can be either wild-type or heterozygous animals, the 9.0-kb and 7.5-kb XbaI fragments
corresponding to the wild-type and deletion alleles, respectively, were detected in genomic DNA extracted from a pool of a single litter of
normally developed embryos which are littermates of mutant embryos. Black arrows indicate mutants. Shown in (a), (c), and (e) are litters
derived from F1 heterozygous mating. Embryos at high magnification are shown in (b), (d), and (f). Embryos photographed at 16 (a), 25
(b), 20 (c), 50 (d), 32 (e), 50 (f) magnification.
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gene expression in skeletal muscle and released the previ-
ously described rostrocaudal restriction of transgene expres-
sion in the segmented axial musculature (Donoghue et al.,
1992; Grieshammer et al., 1992) with a corresponding
decrease in methylation of both proximal and distal MLC
regulatory sequences contained in the transgene (Ceccarelli
et al., 1999). It is likely that the MLC1f/3f locus is normally
inaccessible to activation in mesodermal lineages until
E9.5, when local interruption of heterochromatic configu-
rations may normally release the activation of tissue-
specific genes (Grieshammer et al., 1995; U. Grieshammer
and N.R., unpublished observations). According to this
scenario, deletion of the 1.5-kb DNA segment containing
the MLC downstream enhancer would alter the early re-
pressive state of chromatin surrounding the MLC1f/3f locus
in mesodermal precursors, rendering it active and acces-
sible for precocious transcription.
Alternatively, the deleted 1.5-kb MLC downstream en-
hancer and flanking region may contain insulator se-
quences (Geyer and Corces, 1992) which prevent the locus
FIG. 4. Expression of MLC1f/3f transcripts during development in MLCE/ mutant and wild-type embryos. (Upper panel) An
MLC-specific antisense probe (described in Fig. 3) detected no transcripts in a E7.5 wild-type embryo. The developing heart (indicated by
black arrows) in an E8.5 embryo shows MLC expression. MLC transcripts were detected in both the developing heart and somites (indicated
by a black fine line) in E9.5 embryo, and in E7.5 mutant embryo. (Lower panel) RT-PCR products were electrophoresed in an 2.4% agarose
gel. Lanes 1–4, E7.5 MLCE/, E7.5 wild-type, E8.5 wild-type, and E9.5 wild-type. Lane M, 100-bp DNA ladder.
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from precocious activation by more distal positive regula-
tory elements. The interactions of insulator sequences with
their binding proteins establish boundaries which inhibit
crosstalk from neighboring regulatory programs. This type
of transcriptional control during development has been
extensively characterized in several systems (Kellum and
Schedl, 1991; Zhao et al., 1995; Cuvier et al., 1998; Bell and
Felsenfeld, 1999). Loss of putative insulator sequences lying
within the 1.5-kb enhancer-containing fragment may there-
fore allow neighboring sequences to influence the promot-
ers of MLC1f3f locus, resulting in precocious transcription.
The low frequency of ES cells carrying the MLCE deletion
(1 in 800 cell lines) precluded the derivation of multiple
lines, to rule out the formal possibility that developmental
defects in MLCE/ mutant embryos might be due to a
secondary mutation arising during ES cell selection. The
correct Mendelian ratio of affected embryos obtained in F2
and F3 outcrosses (see Results) argues against a second
unlinked mutation, however. A second closely linked mu-
tation might cause the embryonic lethality seen in the
MLCE/ mutant embryos, although this is inconsistent
with the nature of the homozygous phenotype, in which
deletion of the MLC downstream enhancer activated pre-
cocious expression from the very locus it is known to
control.
Normal Gene Regulation in MLCE/ Heterozygotes
From the phenotype of MLCE/ mutant embryos, it
would be expected that heterozygotic embryos carrying
only one MLC downstream enhancer-deleted locus would
precociously express MLC transcripts from that allele.
Surprisingly, MLC1f/3f transcripts were not present in E7.5
heterozygous embryos, all of which developed normally. It
is possible that normal mesodermal development would
not be affected by low-level ectopic transcription of the
MLC1f/3f locus generated by a single mutant allele.
Alternatively, the presence of the MLC downstream
enhancer on one allele in MLCE/ heterozygotes may be
sufficient to silence MLC1f/3f transcription from the other
allele. The phenomenon of enhancer transvection is not
without precedent (reviewed by Wu, 1993; Blackwood and
Kadonaga, 1998), and could explain how chromosome pair-
ing would allow the intact enhancer on one chromosome to
silence the allelic promoters from the other enhancerless
MLC1f/3f locus in the MLCE/ heterozygotes.
Mesodermal Deficiencies in MLCE/
Mutant Embryos
The results presented in this report suggest that preco-
cious transcription activated from the MLC1f/3f locus may
interfere with functions of cells in the mesodermal lineage
during early embryogenesis. MLC transcripts cannot be
detected in normally developing mouse embryos at E7.5 in
our own study and others (Lyons et al., 1990; Grieshammer
et al., 1992; Kelly et al., 1995; Mcgrew et al., 1996).
Nonetheless, these transcripts are expressed in the
MLCE/ mutant embryos at E7.5, at which stage all three
germ layers are just formed.
How might precocious production of contractile protein
components interfere with normal mesodermal develop-
ment? MLC1f and MLC3f are muscle-specific proteins
associated with the thick filament in vertebrate fast muscle
fibers. A myosin molecule consists of two myosin heavy
chains (MHC) and four MLCs. The light chains are classi-
fied into two classes: the phosphorylatable or regulatory
light chain (RLC), i.e., MLC2f, and the alkali or nonphos-
phorylatable light chain (essential light chain, ELC), i.e.,
MLC1f and MLC3f (Robert et al., 1984). In skeletal muscles,
smooth muscles, and nonmuscle cells, each MHC associ-
ates with two light chains, one from each class. The MLC1f
and MLC3f skeletal muscle isoforms are functionally re-
lated and they can associate with MHC either in ho-
modimers or in heterodimers.
Sequence and domain-structure comparison have demon-
strated strong similarities between nonmuscle myosin II
and muscle myosin in the globular regions which contain
the ATP binding site and the site to which actin binds, and
in the rodlike tail regions (C-terminal) (reviewed by Korn
and Hammer, 1988; Ruppel and Spudich, 1996; Bresnick,
1999). It is postulated that the bipolar filaments of non-
muscle myosin II interact with actin filaments in the same
way as muscle myosin thick filaments do. The state of
nonmuscle myosin II structure is affected by phosphoryla-
tion of RLCs. The phosphorylated RLCs of nonmuscle
myosin control both actomyosin activity and myosin fila-
ment assembly (reviewed by Sweeney et al., 1993; Trybus,
1994). More importantly, phosphorylation of RLCs trans-
forms nonmuscle myosin from a folded 10S to an extended
6S conformation, induces the assembly of bipolar filaments,
and switches “on” the myosin-ATP interaction with actin
(Rowe et al., 1992; Post et al., 1994). The property of this
configuration shift of myosin II in nonmuscle cells is
distinct from that in skeletal and cardiac muscle in which
myosin presents in stable thick filaments.
It is likely that early onset of MLC1f/3f transcription in
cells of the mesodermal lineage in MLCE/ mutant em-
bryos may dramatically expand the pool of ELCs, resulting
in an imbalance between the amounts of RLC and ELC
molecules. Skeletal, smooth muscle and nonmuscle myo-
sins can coassemble into hybrid heteropolymers with mor-
phological feature intermediate between those of the re-
spective homopolyers (Citi et al., 1987). Excessive ELCs in
MLCE/ mutants may compete with RLCs for the binding
sites on the nonmuscle myosin heavy chain, leading to the
generation of RLC-deficient myosin. Removal of the RLC
from myosin or RLC-deficient myosin in nonmuscle cells
produces nonphosphorylatable myosin molecules that are
folded into a compact configuration (Citi and Kendrick-
Jones, 1987) and are essentially “off,” with little actin-
activated ATPase activity and slow velocity of actin move-
ment in a motility assay (Trybus et al., 1994). Myosin II
plays a role in all stages of cytokinesis (reviewed by Ma-
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civer, 1996). Thus, the early embryonic lethality in the
MLCE/ mutants may be caused by defects in cytokinesis
resulting in the failure of cell replicative capacity during
gastrulation. Alternatively, motility-associated cell func-
tions in the mesodermal development during early embryo-
genesis could be impaired by the presence of nonphosphor-
ylatable myosin II, resulting in the failure to gastrulate
properly. Indeed, disruption of cellular functions due to an
inappropriate expression of myosin light chains has re-
cently been demonstrated in smooth and cardiac muscle
development (Huang et al., 1999; James et al., 1999; Sanbe
et al., 1999).
A variation in the ratio between normally phosphorylatable
myosin and nonphosphorylatable MLC1f/3f-containing myo-
sin in nonmuscle cells of mutant embryos might also
account for the variability in penetrance of the MLCE/
phenotype. Once enough phosphorylated myosin II mol-
ecules are present in nonmuscle cells, the functions of the
cells are maintained, perhaps explaining why a small num-
ber of homozygotes (less than 1.7%) developed through E7.5
and to term with no defects. Alternatively, the few survived
homozygous mice may be raised from the mixed genetic
background (129/Sv  C57BL/6J), since variability in phe-
notype due to the genetic background is not unusual in
other knockout mice (George et al., 1993; Simpson et al.,
1997).
It is formally possible that the removal of the 1.5-kb
region containing the MLC downstream enhancer affects
the activity of a linked gene that causes the observed
phenotype. The disruption of regulatory circuitry in neigh-
boring genes by targeted mutagenesis has well been docu-
mented in the MRF4 locus (Olson et al., 1996; Kaul et al.,
2000). Since the original submission of this article, we have
searched the public genome databases for genes flanking the
MLC locus in the human and mouse, perturbation of which
might contribute to the phenotype of MLCE/ mutant
embryos. Unfortunately, the MLC locus and flanking genes
fall into a region that has not been sequenced or assembled
in either human or mouse genome public databases at
present, and this issue remains to be resolved upon comple-
tion of the genome projects.
Multiple Roles of Myosin in Development
Functional defects of nonmuscle myosin can lead to
developmental failure in a variety of organisms. In Dictyo-
stelium, the mutation at the site of phosphorylation in RLC
resulting in RLC-deficient myosin leads to developmental
defects (Chen et al., 1994; Chaudoir et al., 1999). Non-
muscle myosin II is required for establishing cellular polar-
ity in Caenorhabditis elegans embryos and the functional
blockage of the myosin by antisense RNA results in embry-
onic partitioning defects and mislocalization of a PAR-1
protein which is a putative Ser/Thr protein kinase (Guo and
Kemphues, 1996). Interestingly, the disruption of ActRIB,
which is a type I transmembrane serine/threonine kinase
receptor, in mice results in similar phenotypes with
smaller, mesoderm-deficient homozygous embryos at E7.5,
which died before gastrulation (Gu et al., 1998), suggesting
that Ser/Thr protein kinase signal transduction pathway
may be affected by precocious MLC expression. In Drosoph-
ila, the normal functions of nonmuscle myosin II are
required for development of imaginal disc and egg chamber
morphogenesis (Edwards and Kiehart, 1996), and the disrup-
tion of myosin II due to a null mutation of RLC leads to the
defects of developing egg in cytoplasmic transport during
oogenesis and axial nuclear migration resulting in smaller
eggs (Wheatley et al., 1995). Further investigation will
provide more direct evidence for the role played by preco-
cious structural gene expression in mesoderm ablation
resulting from deletion of the MLC downstream enhancer,
by identifying which cell types precociously express
MLC1f/3f locus and which myosin light chains are ex-
pressed, by early overexpression of MLC1f/3f in transgenic
animals, and by quantification of both phosphorylatable
and nonphosphorylatable myosin II in nonmuscle cells via
in vivo or in vitro manipulation of mutant embryos.
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